MA39090B2 - Anticorps anti-ccl17 - Google Patents

Anticorps anti-ccl17

Info

Publication number
MA39090B2
MA39090B2 MA39090A MA39090A MA39090B2 MA 39090 B2 MA39090 B2 MA 39090B2 MA 39090 A MA39090 A MA 39090A MA 39090 A MA39090 A MA 39090A MA 39090 B2 MA39090 B2 MA 39090B2
Authority
MA
Morocco
Prior art keywords
antibodies
ccl17
ccl17 antibodies
polynucleotides
fragments
Prior art date
Application number
MA39090A
Other languages
English (en)
Other versions
MA39090A1 (fr
Inventor
Ken Boakye
Vecchio Alfred Del
John Kehoe
Eilyn Lacy
Lynne Murray
Mary Ryan
Sandra Santulli-Marotto
John Wheeler
Brian Whitaker
Alexey Teplyakov
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA39090A1 publication Critical patent/MA39090A1/fr
Publication of MA39090B2 publication Critical patent/MA39090B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des anticorps se liant spécifiquement à ccl17, des polynucléotides codant ces anticorps ou fragments, et des méthodes de préparation et d'utilisation desdits anticorps et polynucléotides.
MA39090A 2013-11-06 2014-11-06 Anticorps anti-ccl17 MA39090B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900596P 2013-11-06 2013-11-06
PCT/US2014/064302 WO2015069865A1 (fr) 2013-11-06 2014-11-06 Anticorps anti-ccl17

Publications (2)

Publication Number Publication Date
MA39090A1 MA39090A1 (fr) 2018-03-30
MA39090B2 true MA39090B2 (fr) 2021-10-29

Family

ID=53007215

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39090A MA39090B2 (fr) 2013-11-06 2014-11-06 Anticorps anti-ccl17

Country Status (33)

Country Link
US (4) US9944697B2 (fr)
EP (2) EP3466445A1 (fr)
JP (1) JP6556742B2 (fr)
KR (1) KR102331054B1 (fr)
CN (1) CN105722531B (fr)
AU (1) AU2014346770B2 (fr)
BR (1) BR112016010071A2 (fr)
CA (1) CA2929166C (fr)
CL (1) CL2016001081A1 (fr)
CR (1) CR20160187A (fr)
CY (1) CY1124445T1 (fr)
DK (1) DK3065774T3 (fr)
DO (1) DOP2016000105A (fr)
EA (1) EA034655B1 (fr)
ES (1) ES2884255T3 (fr)
HR (1) HRP20211234T1 (fr)
HU (1) HUE058272T2 (fr)
IL (1) IL245488B (fr)
LT (1) LT3065774T (fr)
MA (1) MA39090B2 (fr)
MX (1) MX2016005982A (fr)
MY (1) MY192757A (fr)
NZ (2) NZ719506A (fr)
PE (1) PE20160856A1 (fr)
PH (1) PH12016500826B1 (fr)
PL (1) PL3065774T3 (fr)
PT (1) PT3065774T (fr)
RS (1) RS62373B1 (fr)
SG (1) SG11201603231XA (fr)
SI (1) SI3065774T1 (fr)
SM (1) SMT202100473T1 (fr)
UA (1) UA119973C2 (fr)
WO (1) WO2015069865A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192757A (en) * 2013-11-06 2022-09-07 Janssen Biotech Inc Anti-ccl17 antibodies
WO2017065203A1 (fr) * 2015-10-14 2017-04-20 日本全薬工業株式会社 Anticorps anti-tarc canine utilisé pour le traitement et le diagnostic de la dermatite atopique canine
WO2017079369A2 (fr) * 2015-11-03 2017-05-11 Glaxosmithkline Llc Nouveaux anticorps
MA43308A (fr) * 2015-11-25 2018-10-03 Visterra Inc Molécules d'anticorps se liant à april et leurs utilisations
CN108250290B (zh) 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
US20230266337A1 (en) * 2020-07-10 2023-08-24 Sekisui Medical Co., Ltd. Composition containing tarc, and method for improving storage stability of tarc
TWI899280B (zh) * 2020-07-10 2025-10-01 日商積水醫療股份有限公司 含有tarc之組成物及tarc之保存穩定性之提升方法
WO2024127277A1 (fr) 2022-12-16 2024-06-20 Glaxosmithkline Intellectual Property Development Limited Méthode de traitement de la douleur à l'aide d'un anticorps anti-ccl17

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US226A (en) 1837-06-03 Samuel goss
US4683985A (en) 1985-01-04 1987-08-04 Dresser Industries, Inc. Lubrication system for a vertical gear unit
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
EP0731842A1 (fr) 1993-12-03 1996-09-18 Medical Research Council Proteines et peptides de liaison recombines
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
AU2246597A (en) 1996-02-12 1997-08-28 Schering Corporation Mammalian dendritic cell chemokine reagents
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002006633A1 (fr) 2000-07-18 2002-01-24 The Charles Machine Works, Inc. Commande a distance d'une machine de forage
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
EP2139924B1 (fr) 2007-03-29 2016-07-06 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
JP4341704B2 (ja) 2007-07-12 2009-10-07 トヨタ自動車株式会社 ハイブリッド車両およびハイブリッド車両の制御方法
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
SI2274008T1 (sl) * 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
WO2010045340A1 (fr) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Procédés d’humanisation et de maturation d’affinité d’anticorps
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2496600A1 (fr) * 2009-11-04 2012-09-12 Fabrus LLC Procédés pour l'optimisation d'anticorps basée sur la maturation d'affinité
PL2506871T3 (pl) 2009-11-30 2017-03-31 Janssen Biotech, Inc Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
CA2797981C (fr) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Proteines heterodimeriques et leurs procedes de production et de purification
EP2420253A1 (fr) 2010-08-20 2012-02-22 Leadartis, S.L. Synthèse de molécules polyvalentes et multifonctionnelles avec un domaine de trimérisation de collagène XV
TW201215405A (en) * 2010-08-25 2012-04-16 Hoffmann La Roche Antibodies against IL-18R1 and uses thereof
WO2012047584A2 (fr) 2010-09-27 2012-04-12 Janssen Biotech, Inc. Macaca fascicularis ccl17
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JP6013915B2 (ja) * 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130171659A1 (en) * 2011-12-28 2013-07-04 Abbott Japan Co., Ltd. Methods of prognosis and diagnosis of rheumatoid arthritis
MY192757A (en) * 2013-11-06 2022-09-07 Janssen Biotech Inc Anti-ccl17 antibodies

Also Published As

Publication number Publication date
SI3065774T1 (sl) 2021-11-30
US20180171007A1 (en) 2018-06-21
CY1124445T1 (el) 2022-07-22
IL245488B (en) 2020-03-31
EP3065774A4 (fr) 2017-06-21
IL245488A0 (en) 2016-06-30
HRP20211234T1 (hr) 2021-11-26
EP3466445A1 (fr) 2019-04-10
PH12016500826A1 (en) 2016-06-13
ES2884255T3 (es) 2021-12-10
US9944697B2 (en) 2018-04-17
EP3065774B1 (fr) 2021-05-26
AU2014346770B2 (en) 2020-05-21
CN105722531B (zh) 2020-03-06
BR112016010071A2 (pt) 2017-12-05
CL2016001081A1 (es) 2016-10-21
CR20160187A (es) 2016-08-04
EA201690942A1 (ru) 2016-09-30
DK3065774T3 (da) 2021-08-23
SMT202100473T1 (it) 2021-09-14
CA2929166A1 (fr) 2015-05-14
US11414484B2 (en) 2022-08-16
KR20160077198A (ko) 2016-07-01
PT3065774T (pt) 2021-08-31
JP6556742B2 (ja) 2019-08-07
KR102331054B1 (ko) 2021-11-24
CA2929166C (fr) 2023-08-22
PE20160856A1 (es) 2016-09-03
US20150125458A1 (en) 2015-05-07
US20210017267A1 (en) 2021-01-21
EA034655B1 (ru) 2020-03-03
RS62373B1 (sr) 2021-10-29
MY192757A (en) 2022-09-07
HUE058272T2 (hu) 2022-07-28
EP3065774A1 (fr) 2016-09-14
US20220348647A1 (en) 2022-11-03
PL3065774T3 (pl) 2021-12-13
LT3065774T (lt) 2021-09-10
CN105722531A (zh) 2016-06-29
SG11201603231XA (en) 2016-05-30
MX2016005982A (es) 2016-08-11
WO2015069865A1 (fr) 2015-05-14
NZ719506A (en) 2022-09-30
UA119973C2 (uk) 2019-09-10
MA39090A1 (fr) 2018-03-30
NZ758354A (en) 2022-09-30
US10829549B2 (en) 2020-11-10
DOP2016000105A (es) 2016-10-31
PH12016500826B1 (en) 2021-09-10
JP2016537024A (ja) 2016-12-01

Similar Documents

Publication Publication Date Title
MA43186B1 (fr) Anticorps se liant spécifiquement à pd-1 et leurs utilisations
MA39090B2 (fr) Anticorps anti-ccl17
MA41669A1 (fr) Anticorps se liant a tau
MA41670A1 (fr) Anticorps se liant a tau
MA40671B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MX374811B (es) Anticuerpos anti-tau y métodos de uso.
UA111818C2 (uk) Антитіло проти csf-1r
CY1122978T1 (el) Αντισωματα εναντι-vla-4
UA110470C2 (ru) Антидот антикоагулянта
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
WO2014160160A3 (fr) Conjugués anticorps-médicaments
MY209528A (en) Anti-il-33 antibodies and uses thereof
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
WO2014059442A3 (fr) Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201491496A1 (ru) Ингибиторы c-концевого домена hsp90
MA44665B1 (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MA49289A (fr) Anticorps se liant à steap-1
EA201890434A1 (ru) Антитела к cd154 и способы их применения
EA201591380A1 (ru) АНТАГОНИСТЫ Kv1.3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MA39347B2 (fr) Protéines de fusion d'uti